Large insurance sales agency call centers are accused of enrolling individuals in plans without consent; more young adults are choosing permanent contraception procedures; widespread frustration with prior authorization requirements hints at potential future measures.
Lawsuit Alleges Scheme of Unauthorized Health Insurance Enrollment
A lawsuit filed in US District Court for the Southern District of Florida alleged that large insurance sales agency call centers engaged in a moneymaking scheme by enrolling individuals into Affordable Care Act (ACA) plans or switching their coverage without their permission, according to Kaiser Health News. The lawsuit claimed that call centers purchased names of individuals from misleading advertisements, leading to unauthorized enrollment or coverage switches. Consumers affected by the alleged scheme, which the suit said targeted low-income individuals, faced disruptions in access to health care providers and medications, as well as financial costs.
Increased Tubal Ligations and Vasectomies Among Young Adults After Roe v Wade Reversal
There has been a significant rise in tubal ligations and vasectomies among young adults in the US following the reversal of Roe v Wade, according to CNN. Researchers observed a notable increase in both tubal ligations and vasectomies among individuals aged 18 to 30 years, with tubal ligations showing twice the rate of increase compared with vasectomies. Experts have expressed concerns about the pressure young people face in making decisions regarding permanent contraception and emphasized the importance of informed decision-making and supportive health care environments.
CMS Considers Further Action on Health Insurance Prior Authorization
CMS is evaluating additional steps to address dissatisfaction with prior authorization, while emphasizing the need for collaboration with the private sector, according to Modern Healthcare. CMS Administrator Chiquita Brooks-LaSure acknowledged the widespread frustration with prior authorization requirements at the American Hospital Association's annual conference in Washington, DC, on Monday. Brooks-LaSure indicated that the agency is open to further action, particularly in response to concerns regarding prescription drugs.
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
2 Commerce Drive
Cranbury, NJ 08512